Middle Cerebral Artery Blood Velocity and Cerebral Blood Flow in Sickle Cell Disease

L.M. Brass, MD; I. Prohovnik, PhD; S.G. Pavlakis, MD; D.C. DeVivo, MD; S. Piomelli, MD; and J.P. Mohr, MD

To understand better the relationship between blood velocity measured by transcranial Doppler and cerebral blood flow measured by the $^{133}$Xe inhalation method, we examined 23 patients undergoing evaluation in the Comprehensive Sickle Cell Center at Columbia University. Blood velocity in the middle cerebral artery was directly related to cerebral flow ($r=0.77$; $p<0.05$). A multivariate analysis in this sample made it possible to improve this correlation to account for more than 90% of the variability in cerebral blood flow by the use of transcranial Doppler measures of velocity and pulsatility along with the patient's age and hematocrit ($r=0.95$; $p<0.001$). It is likely that the combination of Doppler and clinical or demographic variables in other diseases will similarly improve the quantitative estimation of cerebral blood flow. (Stroke 1991;22:27-30)

In 1982, the transcranial Doppler (TCD) ultrasound device was introduced which, by using a lower frequency probe, was able to record blood velocity from the basal cerebral arteries through an intact cranium. The TCD device is becoming accepted as a useful tool for the evaluation of intracranial stenosis, vasospasm, and the intracranial hemodynamics associated with occlusive carotid disease. Transcranial Doppler measures blood velocity, but it is not yet possible to measure intracranial vessel diameters reliably using ultrasound techniques, so direct calculations of cerebral blood flow (CBF) (mean arterial blood velocity x cross-sectional area) cannot be made. Few studies have explored the relationship between blood velocity, as measured by TCD, and CBF, and the correlations have been poor. We report our experience with the relationship between CBF, blood velocity, and related clinical indexes in patients with sickle cell disease.

Materials and Methods

We studied our patients as part of an ongoing prospective investigation of sickle cell anemia. Of the 100 patients entered into this registry at the time of this study, 25 patients were studied by TCD, 58 had regional CBF determination by the $^{133}$Xe inhalation technique, and 23 had both CBF and TCD studies. Nine of these 23 patients were men or boys; two had hemoglobin SC disease, one had hemoglobin S thalassemia disease, and the remainder had hemoglobin SS disease. The mean age was 23 years (range, 6–51).

Of the 23 patients included in this analysis, 20 had both the TCD and CBF determination performed on the same day, usually within 1 hour of each other. Blood pressure, hematocrit, and PCO$_2$ were routinely measured at the time of the CBF study.

The Doppler device used (model TC2-64, EME, Ueberlingen, FRG) is a microcomputer-controlled directional Doppler operating at 2 MHz pulsed ultrasound, with a 64-point fast Fourier transform spectrometer analyzer. The transcranial probe uses a focused beam operating at depths of 25–155 mm, electronically adjustable in steps of 5 mm; pulse repetition frequency is 5–10 kHz with a sound intensity range of 10–100 mW/cm$^2$, pulse length 13 μsec, gate width 13 μsec, vessel wall filter 150 Hz, and low pass filter 10 kHz. The output is displayed on a CRT screen as a plot of time versus Doppler shift. Results were stored
on a Tandy Model 100 computer (Tandy Corp., Ft. Worth, Tex.) using customized software from CUZN Consulting, New York.

Transcranial Doppler recordings were made of both middle cerebral arteries (MCAs). All studies were performed with the patient in bed and with the head elevated no more than 30°. Readings at depths of 45, 50, and 55 mm were used as the proximal MCA. The arithmetic mean of these six readings (three from each side) was used in all calculations. At each depth, the systolic velocity (V_{systolic}), mean velocity (V_{mean}), and systolic velocity-to-diastolic velocity ratio were recorded. From these data, the diastolic velocity (V_{diastolic}), pulsatility index (PI) ([V_{systolic} - V_{diastolic}]/V_{mean}), and pulsatility transmission index (PI/P_{reference vessel}) were calculated.

Cerebral blood flow analysis was performed using the $^{133}$Xe inhalation method for determining flow on a Novo Cerebrograph 32c (Novo Diagnostic Systems, Copenhagen, Denmark) with 32 detectors. Compartamental size variables were also calculated: f$_{1}$, fast-compartment (gray matter) flow, in milliliters per 100 grams per minute; p$_{f}$, fast-compartment (gray matter) weighting coefficient; p$_{v}$, vascular compartment size; and pr$_{v}$, ratio of vascular to fast-compartment size.

The rationale and our experience with these measurements in patients with sickle cell disease have been reported previously, as have the details of the technique and quality control procedures. The arithmetic mean of both hemispheres was used in the calculations. f$_{1}$ was used as the measure of CBF, derived with the six-unknown model.

Analysis included “best” model by forward, stepwise, and backward procedures using $F$ tests. Statistical analysis was performed on an Apple Macintosh II using DATADESK PROFESSIONAL (Odesta Corporation, Northbrook, Ill.) and on an IBM System 2 PC using SAS Version 6 (Statistical Analysis System, Cary, N.C.).

Results

For the 23 patients studied, mean hematocrit was 25% (range, 10–38), mean systolic velocity in the MCA was 153 cm/sec (range, 68–289), and mean CBF was 124 ml/100 g/min (range, 64.9–193).

Ten of the 23 patients had abnormal magnetic resonance imaging (MRI) (usually suggesting distal field infarction), seven had a clinical history of stroke (all of these had abnormal MRI), and only one within a week of TCD and CBF. Three had received transfusion therapy. All patients except for systolic and diastolic blood pressure (23 patients) were used, then a second analysis was performed with all variables (19 cases). With this analysis, only the systolic and diastolic velocities, hematocrit, age, and pulsatility index entered the model. The equation for CBF = 1.36 - V_{systolic} - 2.04 - V_{diastolic} - 2.99 - hematocrit - 0.828 - age - 151 - PI + 282 was able to predict more than 90% of the variability in CBF. This model was highly significant (r=0.947; p£0.001). Table 2 summarizes the results of this regression.

Discussion

This study confirms the increased CBF reported in sickle cell disease* and demonstrates a similar effect.
TABLE 1. Pearson Correlation Coefficients for Clinical, Transcranial Doppler, and Cerebral Blood Flow Measures

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>Standard Error</th>
<th>F</th>
<th>Probability&gt;F</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>f&lt;sub&gt;1&lt;/sub&gt;</td>
<td>1.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V&lt;sub&gt;s&lt;/sub&gt;</td>
<td>0.774*</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V&lt;sub&gt;m&lt;/sub&gt;</td>
<td>0.782*</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V&lt;sub&gt;d&lt;/sub&gt;</td>
<td>0.713*</td>
<td>0.001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI</td>
<td>-0.448*</td>
<td>-0.563*</td>
<td>-0.648*</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>-0.320</td>
<td>-0.257</td>
<td>-0.263</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td>Hct</td>
<td>-0.788*</td>
<td>-0.638*</td>
<td>-0.683*</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td>SyBP</td>
<td>-0.288</td>
<td>-0.022</td>
<td>-0.018</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td>DiBP</td>
<td>-0.437*</td>
<td>-0.420*</td>
<td>-0.563*</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td>ISI</td>
<td>0.943*</td>
<td>0.708*</td>
<td>0.629*</td>
<td>0.00001</td>
<td></td>
</tr>
<tr>
<td>Pr&lt;sub&gt;f&lt;/sub&gt;</td>
<td>0.938*</td>
<td>0.717*</td>
<td>0.631*</td>
<td>-0.397*</td>
<td></td>
</tr>
<tr>
<td>Pr&lt;sub&gt;4&lt;/sub&gt;</td>
<td>0.909*</td>
<td>0.794*</td>
<td>0.768*</td>
<td>-0.629*</td>
<td></td>
</tr>
<tr>
<td>Pi&lt;sub&gt;4&lt;/sub&gt;</td>
<td>0.536*</td>
<td>-0.572*</td>
<td>-0.629*</td>
<td>0.00001</td>
<td></td>
</tr>
</tbody>
</table>

f<sub>1</sub>, cerebral blood flow; V<sub>s</sub>, systolic velocity; V<sub>m</sub>, mean velocity; V<sub>d</sub>, diastolic velocity; PI, pulsatility index; Hct, hematocrit; SyBP, systolic blood pressure; DiBP, diastolic blood pressure; ISI, initial slope index; pr<sub>f</sub>, fast-compartment weighting coefficient; Pr<sub>4</sub>, vascular compartment size; Pi<sub>4</sub>, ratio of vascular to fast-compartment size.

**P<0.001, 0.05, 0.10, respectively.**

on blood velocity. Early work with TCD suggested that blood velocity might correlate with blood flow. Parallel changes were noted between velocity and flow during carotid endarterectomy, 8,9 hypercapnia, 10,11 and vasomotor stimuli. 11,12 However, attempts of a direct correlation were poor 12,13 or existed only at low flows. 14

Bishop et al 12 correlated changes in blood velocity and CBF in response to hypercapnia expressed as a reactivity index (r=0.849), but their direct correlation between MCA velocity and hemispheric CBF was also poor (r=0.424; p<0.01). A high incidence of carotid artery disease may have contributed to their low correlation. 8-13,15 Sorteberg et al 16 were able to improve their correlation between velocity and flow (r=0.26) by normalizing to a standard PCO2 (r=0.63).

The weak correlations reported by other groups in part may be explained by examining the theory behind the analysis used in comparison studies. In the extreme, with measurements made over a narrow range of values, the correlation coefficient will approach zero, even when nearly complete agreement actually exists. 17 Blood velocities from the data of Bishop et al 12 ranged approximately 100 cm/sec (from 40 to 140 cm/sec); from that of Sorteberg et al, 16 48 cm/sec (54-102); and from that of Halsey et al, 14 velocities ranged 80 cm/sec (15-95) before clamping and 116 cm/sec (16-132) after clamping. In our cohort, blood velocities ranged 221 cm/sec (68-289).

Pulsatility, a measure of proximal resistance, 4,18 correlated poorly with CBF. However, there was a weak correlation between the pulsatility and CBF compartmental size variables, especially pr<sub>f</sub> (r=0.572; p<0.005). In patients with an abnormal MRI, the correlation was higher (r=0.729; p<0.05) than for those with a normal MRI (r=0.447; p<0.15). It is possible that the decreases in pulsatility and increases in pr<sub>f</sub> (representing an increased blood volume) in patients with an abnormal MRI were related to large-vessel occlusive disease. 19,20 This would be consistent with the MRIs suggesting distal field infarction and observations that sickle cell disease patients with central nervous system infarctions have an association with occlusive disease in the internal carotid and proximal intracranial arteries. 21

This study reintroduces the possibility of using TCD measurements of blood velocity in the MCA, along with simple clinical and laboratory information, as an index of CBF with more complex mathematical analysis than has been previously applied. In this particular population, hematocrit alone is a powerful predictor of CBF, as is shown in Table 1.

### Table 2. Results of Regression Model for Cerebral Blood Flow

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>Standard Error</th>
<th>F</th>
<th>Probability&gt;F</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constant</td>
<td>282</td>
<td>42.7</td>
<td>43.71</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>V&lt;sub&gt;s&lt;/sub&gt;</td>
<td>1.36</td>
<td>0.308</td>
<td>9.27</td>
<td>0.0073</td>
<td></td>
</tr>
<tr>
<td>V&lt;sub&gt;d&lt;/sub&gt;</td>
<td>-2.04</td>
<td>0.543</td>
<td>21.37</td>
<td>0.0002</td>
<td></td>
</tr>
<tr>
<td>Hct</td>
<td>-2.99</td>
<td>0.646</td>
<td>19.60</td>
<td>0.0004</td>
<td>0.0485</td>
</tr>
<tr>
<td>Age</td>
<td>-0.628</td>
<td>0.272</td>
<td>14.14</td>
<td>0.0016</td>
<td>0.0496</td>
</tr>
<tr>
<td>PI</td>
<td>-151</td>
<td>57.3</td>
<td>6.92</td>
<td>0.0176</td>
<td>0.0663</td>
</tr>
</tbody>
</table>

R<sup>2</sup>=89.6%; r=0.947; s=13.91 with 17 degrees of freedom (df) (23 observations). For regression, df=5 and F ratio=29.2; for residual, F ratio=17.
Hematocrit explains approximately 62% of CBF variability. For coarse estimates, therefore, no other measurements are necessary in this circumstance. However, the addition of several TCD variables and age raises the proportion of explained variance to more than 90%. In this population, TCD thus can improve the prediction of CBF by this amount over the hematocrit alone and allows for finer distinction and more precise follow-up. It is likely that the introduction of TCD to other clinical or demographic variables in other diseases will contribute similarly.

References

KEY WORDS • blood flow velocity • anemia, sickle cell • cerebral blood flow • ultrasonics
Middle cerebral artery blood velocity and cerebral blood flow in sickle cell disease.
L M Brass, I Prohovnik, S G Pavlakis, D C DeVivo, S Piomelli and J P Mohr

doi: 10.1161/01.STR.22.1.27

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1991 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/22/1/27

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in
Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.
Once the online version of the published article for which permission is being requested is located, click Request
Permissions in the middle column of the Web page under Services. Further information about this process is
available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/